Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance.
10.1186/s40880-015-0029-3
- Author:
Xiao XU
1
Author Information
1. ACEA Biosciences Inc., San Diego, CA, 92121, USA. xxu@aceabio.com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
Carcinoma, Non-Small-Cell Lung;
China;
Drug Resistance, Neoplasm;
Humans;
Lung Neoplasms;
Multicenter Studies as Topic;
Mutation;
Pharmacogenetics;
Precision Medicine;
Receptor, Epidermal Growth Factor
- From:Chinese Journal of Cancer
2015;34(7):285-287
- CountryChina
- Language:English
-
Abstract:
Avitinib, a new generation inhibitor of epidermal growth factor receptor (EGFR), was approved for clinical trial in both China and the United States, and the phase 1 trials were initiated in both countries in parallel. In the preclinical studies, avitinib showed three novel features including (1) irreversibly binding EGFR by forming a covalent bound with Cys 797 in the ATP-binding pocket, (2) sparing wild-type EGFR, and (3) overcoming T790M-induced resistance. Avitinib is the first China-developed novel EGFR inhibitor that has entered in global clinical trials, and will provide a precision targeted therapy for non-small cell lung cancer patients.
